CytoMed Therapeutics (NASDAQ:GDTC – Get Free Report)‘s stock had its “speculative buy” rating reaffirmed by equities researchers at Benchmark in a research report issued on Thursday, Benzinga reports. They currently have a $5.00 price target on the stock. Benchmark’s target price would indicate a potential upside of 145.10% from the company’s current price.
CytoMed Therapeutics Trading Up 1.5 %
Shares of NASDAQ GDTC opened at $2.04 on Thursday. CytoMed Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $5.50. The stock has a fifty day moving average of $1.64 and a 200-day moving average of $1.92.
CytoMed Therapeutics Company Profile
Further Reading
- Five stocks we like better than CytoMed Therapeutics
- Investing In Automotive Stocks
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- What is the Dow Jones Industrial Average (DJIA)?
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Overbought Stocks Explained: Should You Trade Them?
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.